All Subin Baral (EY Global) articles
-
ReportPharma Horizons: Trends in Pharmaceutical Manufacturing
EPR’s 2026 pharma manufacturing trends report covers the key developments in supply chain, quality, drug development, new modalities and beyond.
-
ArticleBiopharma dealmaking: predictions for 2024
EPR speaks to Subin Baral, EY Global Deals Leader, Life Sciences about biopharma dealmaking in 2023 and the investment outlook for 2024.
-
ArticleDivest to invest: the new normal in biopharma?
Subin Baral, EY Global Deals Leader for Life Sciences, a partner at Ernst & Young LLP, shares exclusive insight on how strategies such as specialisation can help life science companies secure future growth and the key role divestments and spin-outs have on ensuring this strategic focus.
-
NewsMajor M&A deals on 2023 agenda, says report
Subin Baral, EY Global Deals Leader, Life Sciences, recounts the global M&A trends in 2022 and predicts activity for 2023 in EY’s 2023 M&A Firepower report.